Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Sagent Pharm Inc (SGNT) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 715,130
  • Shares Outstanding, K 33,090
  • Annual Sales, $ 318,300 K
  • Annual Income, $ -21,880 K
  • 36-Month Beta 1.65
  • Price/Sales 2.25
  • Price/Book 2.83
  • Price/Earnings ttm 53.00
  • Earnings Per Share ttm 0.41
  • Most Recent Earnings 0.02 on 05/03/16
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.64 +0.55%
on 08/01/16
21.88 -0.55%
on 08/10/16
+0.07 (+0.32%)
since 07/29/16
3-Month
12.40 +75.48%
on 05/31/16
21.88 -0.55%
on 08/10/16
+9.41 (+76.19%)
since 05/27/16
52-Week
10.55 +106.26%
on 05/03/16
21.88 -0.55%
on 08/10/16
+1.72 (+8.58%)
since 08/28/15

Most Recent Stories

More News
Nichi-Iko Pharmaceutical Co., Ltd. Announces Results of Tender Offer to Purchase All of the Outstanding Shares of Common Stock of Sagent Pharmaceuticals, Inc.

Nichi-Iko Pharmaceutical Co., Ltd. (TSE:4541) ("Nichi-Iko" or "Parent") today announced the results of its tender offer to purchase all of the outstanding shares of common stock of Sagent...

Chemical Financial Set to Join S&P MidCap 400; Supervalu, Shoe Carnival and Eagle Pharmaceuticals to Join S&P SmallCap 600

S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600 indices:

Sagent Pharmaceuticals Initiates a Nationwide Voluntary Recall of Oxacillin for Injection, USP, 10 g due to presence of iron oxide particulate matter

Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the voluntary nationwide recall of one lot of Oxacillin for Injection, USP, 10 g (NDC 25021-163-99) Lot OXT512 (Exp. Date March 2017) manufactured...

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Sagent Pharmaceuticals, Inc. (SGNT)

Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Sagent Pharmaceuticals, Inc. ("Sagent" or the "Company") (Nasdaq:SGNT) in the United States District Court for the...

Nichi-Iko Pharmaceutical Co., Ltd. Announces Expiration of HSR Waiting Period for Proposed Acquisition of Sagent Pharmaceuticals, Inc.

Nichi-Iko Pharmaceutical Co., Ltd. (TSE: 4541) ("Nichi-Iko" or "Parent") and Shepard Vision, Inc. ("Purchaser") announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements...

Sagent Pharmaceuticals Sets Date and Time for Release of Fourth Quarter and Full Year 2015 Financial Results

Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) a leader of specialty pharmaceutical products with a specific emphasis on the injectable market, today announced that it will release financial results for the...

Why Sagent Pharmaceuticals Inc. Jumped Today

What: Sagent Pharmaceuticals surged this morning and was up as much as 19% today after Reuters reported that the company has hired an investment bank to solicit bids to buy the generic-drug maker....

Sagent Pharmaceuticals Receives Innovative Technology Designation From Novation for GLYDO(R) (Lidocaine HCl Jelly USP, 2%)

Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) announced its GLYDO(R) (lidocaine HCl jelly USP, 2%) has received Innovative Technology designation from Novation, the leading healthcare services company that...

Sagent Pharmaceuticals to Present at 34th Annual J.P. Morgan Healthcare Conference

Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced that it will present at the 34 Annual J.P. Morgan Healthcare...

Timing is Crucial, Upside Analysis - Analyst Notes on Sagent Pharmaceuticals, Del Frisco's Restaurant Group, Air Transport Services Group and Edge Therapeutics

NEW YORK, NY / ACCESSWIRE / December 24, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Sagent Pharmaceuticals...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Sagent Pharmaceuticals, Inc. is a pharmaceutical company that develops and sources products with primary focus on generic injectable pharmaceuticals. Products offered by the Company cover a range of anti-infective, oncolytic and critical care indications in a variety of presentations, including single-...

See More

Support & Resistance

2nd Resistance Point 21.77
1st Resistance Point 21.77
Last Price 21.76
1st Support Level 21.75
2nd Support Level 21.73

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.